SCHEMBL16397222

SCHEMBL16397222

CC(NC(=O)OC(C)(C)C)c1cccc(-c2cc(COc3ccccc3CC(=O)OC(C)(C)C)cc(NCC3CC3)c2)c1F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CFD P00746 8/20 0.38
▸ F11 P03951 7/20 0.35
▸ TPSB2 P20231 4/20 0.35
▸ CACNA1B Q00975 2/20 0.34
▸ ATM Q13315 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ PTGER1 P34995 2/20 0.33
▸ PTGER4 P35408 2/20 0.33
▸ PTGER3 P43115 2/20 0.33
▸ PTGER2 P43116 2/20 0.33
▸ MEN1 O00255 1/20 0.32
▸ ACACB O00763 2/20 0.32
▸ ACACA Q13085 2/20 0.32
▸ PTPN1 P18031 1/20 0.32
▸ KLKB1 P03952 4/20 0.32
▸ PLG P00747 2/20 0.32
▸ PLAU P00749 2/20 0.32
▸ F7 P08709 2/20 0.32
▸ F2 P00734 1/20 0.32
▸ F9 P00740 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16410408 1.00 CFD (0.38) CFDF11TPSB2CACNA1BATM
SCHEMBL16410420 0.97 CFD (0.38) CFDF11TPSB2CACNA1BATM
SCHEMBL16410261 0.97 CFD (0.38) CFDF11TPSB2CACNA1BATM
SCHEMBL16397406 0.94 CFD (0.44) CFDF11TPSB2ATMPTGER1
SCHEMBL16397383 0.92 CFD (0.43) CFDF11TPSB2CACNA1BPTGER1
SCHEMBL16410483 0.91 CFD (0.37) CFDF11TPSB2CACNA1BPTGER1
SCHEMBL17764425 0.90 CFD (0.38) CFDF11TPSB2CACNA1BPTGER1
SCHEMBL16410316 0.90 L3MBTL1 (0.36) CFDF11TPSB2CACNA1BKMT2A
SCHEMBL16410314 0.90 L3MBTL1 (0.36) CFDF11TPSB2CACNA1BKMT2A
SCHEMBL17764260 0.90 CFD (0.39) CFDF11TPSB2PTGER1PTGER4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof NOVARTIS AG (CH) 2016-05-26 — — US disclosed
EP-3022182-A1 AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF Novartis AG (CH) 2016-05-25 — — EP disclosed
WO-2015009977-A1 AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF NOVARTIS AG (CH) 2015-01-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof CFD, CFH, CFB CFD 1/4885F11 17/4885TPSB2 248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback